Aptar Pharma to unveil new standard for injectables particulate reduction

Aptar Pharma, a drug delivery systems provider, will introduce the latest advancements in its premium portfolio of stoppers, when it exhibits at A3P’s Congrès International in November

A3P’s Congrès International takes place from 14-16 November 2017 at the Congress Center, Biarritz, France.

This event welcomes nearly 650 professionals from the pharmaceutical and biotech industries to gain and share insight about current market innovations. This year’s exhibition themes are sterilisation, single-use applications and regulation.

Aptar Pharma will showcase its pioneering coated stopper, PremiumCoat, which is setting the standard for coated stoppers by offering a reduction in particulates.

It features a Fluorinated (ETFE) film, which is applied during the manufacturing process. This approach delivers a homogenised coating, the established method to create a robust and effective barrier.

The development of PremiumCoat is an innovative response to the pharmaceutical and biotech market’s increased need for more inert stoppers, reinforcing Aptar Pharma’s market leadership in addressing challenges within the injectables market.

Arnaud Fournier, Aptar Pharma’s Senior Business Project Manager for Injectables, said: “We look forward to sharing our latest development, PremiumCoat, with delegates at A3P’s Congrès International in November. PremiumCoat combines years of elastomer development expertise with best practices in coating technology and we are excited to demonstrate the latest example of our commitment to meeting our customer’s needs.”

Aptar Pharma will exhibit at A3P Congrès International: stand 85